(Cys(Bzl)84,Glu(OBzl)85)-CD4 (81-92)

(Cys(Bzl)84,Glu(OBzl)85)-CD4 (81-92) (CPC catalog code HIV-005) is a synthetic viral / antiviral research peptide in the viral peptides category. It is provided as a lyophilized ~1 mg vial for in-vitro research use only.

Published and internal research programs use (Cys(Bzl)84,Glu(OBzl)85)-CD4 (81-92) as a reference standard in viral peptides workflows — for example, viral fusion and entry-inhibitor screening and viral protease activity and inhibitor discovery. Human clinical evidence is not established.

No. (Cys(Bzl)84,Glu(OBzl)85)-CD4 (81-92) is a research-grade reference peptide and is not approved by the FDA or any national regulator for human or veterinary therapeutic use. It is offered exclusively for in-vitro laboratory research and does not ship to the United States for consumer use.

In a viral peptides workflow, (Cys(Bzl)84,Glu(OBzl)85)-CD4 (81-92) is reconstituted in sterile buffer or DMSO (solubility-dependent) and applied in the researcher's chosen assay format. Pseudovirus entry, plaque-reduction, protease-activity, and ELISA readouts.

Store lyophilized at −20 °C under BSL-appropriate conditions where required. Follow your institution's standard operating procedures for handling synthetic peptides.

This kindr reference page mirrors CPC Scientific's catalog metadata for HIV-005. The upstream reference sheet — including sequence, purity, MW, and application notes where published — is linked from the buy panel. All orders placed on kindr Peptides ship internationally under research-use terms only.

Research-grade peptides in the CPC catalog are synthesized by solid-phase peptide synthesis (SPPS), purified by preparative RP-HPLC, and characterized by analytical HPLC and mass spectrometry. Typical purity is ≥95%; certificate of analysis is available on request.